KRAS genetic variant as a prognostic factor for recurrence in resectable non-small cell lung cancer

被引:11
|
作者
Sullivan, I. [1 ]
Salazar, J. [2 ,3 ]
Arqueros, C. [1 ]
Andres, M. [1 ]
Sebio, A. [1 ]
Majem, M. [1 ]
Szafranska, J. [4 ]
Martinez, E. [5 ]
Paez, D. [1 ]
Lopez-Pousa, A. [1 ]
Baiget, M. [2 ,3 ]
Barnadas, A. [1 ,6 ]
机构
[1] Hosp Santa Creu & Sant Pau, Med Oncol Dept, Barcelona, Spain
[2] Hosp Santa Creu & Sant Pau, Genet Dept, St Antoni Maria Claret 167, Barcelona 08025, Spain
[3] CIBERER, U 705, Barcelona, Spain
[4] Hosp Santa Creu & Sant Pau, Pathol Dept, Barcelona, Spain
[5] Hosp Santa Creu & Sant Pau, Thorac Surg Dept, Barcelona, Spain
[6] UAB, Barcelona, Spain
来源
CLINICAL & TRANSLATIONAL ONCOLOGY | 2017年 / 19卷 / 07期
关键词
Resectable non-small cell lung cancer; Prognostic marker; VEGF pathway; KRAS; Genetic variants; ENDOTHELIAL GROWTH-FACTOR; PHARMACOGENETIC FACTORS; PATHWAY POLYMORPHISMS; VEGF POLYMORPHISMS; EXPRESSION; SURVIVAL; ANGIOGENESIS; CHEMOTHERAPY; ASSOCIATION; BEVACIZUMAB;
D O I
10.1007/s12094-017-1620-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Several angiogenic prognostic markers are under investigation because of their potential clinical utility, aiming to improve patient outcomes. We hypothesized that genetic variant in the VEGF pathway could be used as prognostic markers of survival in non-small cell lung cancer (NSCLC) patients undergoing pulmonary resection. Methods We evaluated the relationship between genetic variants in the VEGF pathway and relapse-free survival (RFS, main endpoint) and overall survival (OS, secondary endpoint) among 131 patients with stage I-III NSCLC treated with surgical resection from 2009 to 2013. Clinical, pathological and surgical data were prospectively collected. Twenty-five variants in sixteen relevant genes were selected and genotyped in tumor samples by real time PCR. The Kaplan-Meier method with the log-rank test and Cox's regression models were used for RFS and OS analyses. Results With a median follow-up of 36 (min = 2.8; max = 67.4) months, there were 31 (24%) relapses and 31 (24%) deaths. Overall, median RFS was not reached and median OS was 65 [95% confidence interval (CI) 56-75] months. The KRAS rs1137282 and PIK3C2A rs4356203 variants were significantly associated with RFS. For KRAS rs1137282, the 3-year RFS was 76% [95% CI 64-84%] in patients harboring an A/A genotype compared to 53% [95% CI 37-69%] in patients harboring an A/G or G/G genotype (p = 0.02). For PIK3C2A rs4356203, patients with an A/A or an A/G genotype had a 3-year RFS of 72% [95% CI 58-76%], whereas in patients with a G/G genotype was 49% [95% CI 28-70%] (p = 0.02). These associations remained statistically significant after adjusting for all the relevant clinical parameters in the multivariable analysis. Conclusion Genetic variants in VEGF pathway may be associated with recurrence in stage I-III NSCLC. Specifically, the KRAS rs1137282 could be considered as a prognostic factor for recurrence in resectable NSCLC patients. Although PIK3C2A rs4356203 was associated with RFS, further analyses are necessary to confirm these data.
引用
收藏
页码:884 / 890
页数:7
相关论文
共 50 条
  • [21] Prognostic Significance of Telomerase Polymorphism in Non-Small Cell Lung Cancer
    Catarino, Raquel
    Araujo, Antonio
    Coelho, Ana
    Gomes, Monica
    Nogueira, Augusto
    Lopes, Carlos
    Medeiros, Rui M.
    CLINICAL CANCER RESEARCH, 2010, 16 (14) : 3706 - 3712
  • [22] KRAS Mutations Impact Clinical Outcome in Metastatic Non-Small Cell Lung Cancer
    Eklund, Ella A.
    Wiel, Clotilde
    Fagman, Henrik
    Akyurek, Levent M.
    Raghavan, Sukanya
    Nyman, Jan
    Hallqvist, Andreas
    Sayin, Volkan, I
    CANCERS, 2022, 14 (09)
  • [23] Tumor angiogenesis as an important prognostic factor in advanced non-small cell lung cancer (Stage IIIA)
    Bacic, Ivan
    Karlo, Robert
    Zadro, Ana Sostaric
    Zadro, Zvonko
    Skitarelic, Neven
    Antabak, Anko
    ONCOLOGY LETTERS, 2018, 15 (02) : 2335 - 2339
  • [24] Tumor Necrosis as a Prognostic Factor for Stage IA Non-Small Cell Lung Cancer
    Park, Seong Yong
    Lee, Hyun-Sung
    Jang, Hee-Jin
    Lee, Geon Kook
    Chung, Kyung Young
    Zo, Jae Ill
    ANNALS OF THORACIC SURGERY, 2011, 91 (06): : 1668 - 1673
  • [25] Targeting the KRAS variant for treatment of non-small cell lung cancer: potential therapeutic applications
    Ricciuti, Biagio
    Leonardi, Giulia Costanza
    Metro, Giulio
    Grignani, Francesco
    Paglialunga, Luca
    Bellezza, Guido
    Baglivo, Sara
    Mencaroni, Clelia
    Baldi, Alice
    Zicari, Daniela
    Crino, Lucio
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2016, 10 (01) : 53 - 68
  • [26] Adjuvant treatment for resectable non-small cell lung cancer
    Lim, Jeong Uk
    JOURNAL OF THE KOREAN MEDICAL ASSOCIATION, 2023, 66 (03): : 173 - 179
  • [27] Neoadjuvant immunotherapy for resectable non-small cell lung cancer
    Xie, Hui
    Shi, Xuejun
    Wang, Guangshun
    AMERICAN JOURNAL OF CANCER RESEARCH, 2021, 11 (06): : 2521 - 2536
  • [28] Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer
    Lochrin, Sarah E.
    Forde, Patrick M.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (08) : 415 - 423
  • [29] Resectable non-small cell lung cancer: an evolving landscape
    Loh, Jerold
    Wijaya, Silvana T.
    Sooi, Kenneth
    Chia, Puey Ling
    Soo, Ross A.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2022, 11 (07) : 1241 - 1246
  • [30] KRAS G12C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancer
    Park, Sehhoon
    Kim, Ji-Yeon
    Lee, Se-Hoon
    Suh, Beomseok
    Keam, Bhumsuk
    Kim, Tae Min
    Kim, Dong-Wan
    Heo, Dae Seog
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2017, 32 (03): : 514 - 522